banner

XING

  • email
  • twitter
  • linkedin
  • facebook
By CNW Group - Jun 13 2022
share
  • email
  • twitter
  • linkedin
  • facebook
Dompé Announces Results of Phase 2 Study Evaluating the Efficacy and Safety of Reparixin in Patients with Severe COVID-19 Pneumonia
In hospitalized patients with COVID-19 Pneumonia, the rates of clinical events among those treated with Reparixin (n=36) were statistically...
By CNW Group - Oct 30 2019
share
  • email
  • twitter
  • linkedin
  • facebook
Janssen Announces Health Canada Approval of DARZALEX® (Daratumumab) in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed Patients With Multiple Myeloma Who Are Transplant Ineligible
This DARZALEX® combination regimen reduced the risk of disease progression or death by 44% in newly diagnosed patients who are transplant...
By CNW Group - May 10 2021
share
  • email
  • twitter
  • linkedin
  • facebook
DOORwaY-90 Study for SIR-Spheres® Therapy as First-Line Treatment for Hepatocellular Carcinoma Enrolls First Patient
Sirtex Medical ("Sirtex"), a leading manufacturer of targeted liver cancer therapies, announced that the first patient has been enrolled in...
https://media.caboodleai.net/pda/companies/4e643680-43ac-4f43-b061-5238281ad800.com.png
Website: https://www.xing.com